U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Metastatic Neuroendocrine Carcinoma

MedGen UID:
781346
•Concept ID:
C3203639
•
Neoplastic Process
Synonym: Neuroendocrine carcinoma, metastatic
SNOMED CT: Neuroendocrine carcinoma, metastatic (435471000124104)

Definition

A neuroendocrine carcinoma that has spread from its original site of growth to another anatomic site. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVMetastatic Neuroendocrine Carcinoma

Professional guidelines

PubMed

Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d'Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network.
Hadoux J, Kanaan C, Durand A, Hescot S, Hautefeuille V, Cadiot G, Tauveron I, Laboureau S, Do Cao C, Walter T, Petorin C, Blanchet O, Jannin A, Gu C, Faron M, Leteurtre E, Rousselet MC, Zakeyh JJ, Marchal A, Chatelain D, Beaulaton C, Hervieu V, Ducreux M, Scoazec JY, Baudin E
Eur J Cancer 2021 Jul;152:100-115. Epub 2021 Jun 3 doi: 10.1016/j.ejca.2021.04.030. PMID: 34090142
A Real-World, Population-Based Study for the Incidence and Outcomes of Neuroendocrine Neoplasms of Unknown Primary.
Abdel-Rahman O
Neuroendocrinology 2021;111(9):876-882. Epub 2020 Sep 25 doi: 10.1159/000511812. PMID: 32980845

Recent clinical studies

Therapy

Genetics-guided therapy in neuroendocrine carcinoma: response to BRAF- and MEK-inhibitors.
Falkman L, Sundin A, Skogseid B, Botling J, Bernardo Y, Wallin G, Zhang L, Welin S, Lase I, Mollazadegan K, Crona J
Ups J Med Sci 2024;129 Epub 2024 Apr 10 doi: 10.48101/ujms.v129.10660. PMID: 38716076Free PMC Article
Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d'Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network.
Hadoux J, Kanaan C, Durand A, Hescot S, Hautefeuille V, Cadiot G, Tauveron I, Laboureau S, Do Cao C, Walter T, Petorin C, Blanchet O, Jannin A, Gu C, Faron M, Leteurtre E, Rousselet MC, Zakeyh JJ, Marchal A, Chatelain D, Beaulaton C, Hervieu V, Ducreux M, Scoazec JY, Baudin E
Eur J Cancer 2021 Jul;152:100-115. Epub 2021 Jun 3 doi: 10.1016/j.ejca.2021.04.030. PMID: 34090142
Metastatic Neuroendocrine Carcinoma of Unknown Origin Arising in the Femoral Nerve Sheath.
Candy N, Young A, Allinson K, Carr O, McMillen J, Trivedi R
World Neurosurg 2017 Aug;104:1047.e1-1047.e6. Epub 2017 May 11 doi: 10.1016/j.wneu.2017.05.013. PMID: 28502684
Amrubicin in patients with platinum-refractory metastatic neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the gastrointestinal tract.
Araki T, Takashima A, Hamaguchi T, Honma Y, Iwasa S, Okita N, Kato K, Yamada Y, Hashimoto H, Taniguchi H, Kushima R, Nakao K, Boku N, Shimada Y
Anticancer Drugs 2016 Sep;27(8):794-9. doi: 10.1097/CAD.0000000000000393. PMID: 27341105
Long-Term Survival with Long-Acting Somatostatin Analogues Plus Aggressive Cytoreductive Surgery in Patients with Metastatic Neuroendocrine Carcinoma.
Deutsch GB, Lee JH, Bilchik AJ
J Am Coll Surg 2015 Jul;221(1):26-36. Epub 2015 Apr 8 doi: 10.1016/j.jamcollsurg.2015.03.055. PMID: 26027502

Prognosis

Metastatic primary breast neuroendocrine neoplasms: a case series.
Batty K, Taylor AM, Bernard EJ, Diakos CI, Clarke SJ, Guminski A, Baron-Hay S, Boyle F, Pavlakis N, Chan DL
Intern Med J 2023 Oct;53(10):1813-1818. Epub 2022 Oct 31 doi: 10.1111/imj.15961. PMID: 36314732
Metastatic rectal neuroendocrine carcinoma presenting with treatment-refractory immune thrombocytopenia: A case report and literature review.
Bancheno WM, Adidam SR, Melaku MA
Medicine (Baltimore) 2022 Jul 22;101(29):e29616. doi: 10.1097/MD.0000000000029616. PMID: 35866784Free PMC Article
Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d'Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network.
Hadoux J, Kanaan C, Durand A, Hescot S, Hautefeuille V, Cadiot G, Tauveron I, Laboureau S, Do Cao C, Walter T, Petorin C, Blanchet O, Jannin A, Gu C, Faron M, Leteurtre E, Rousselet MC, Zakeyh JJ, Marchal A, Chatelain D, Beaulaton C, Hervieu V, Ducreux M, Scoazec JY, Baudin E
Eur J Cancer 2021 Jul;152:100-115. Epub 2021 Jun 3 doi: 10.1016/j.ejca.2021.04.030. PMID: 34090142
Metastatic malignant melanoma with neuroendocrine differentiation: a case report and review of the literature.
Juhlin CC, Zedenius J, Haglund F
J Med Case Rep 2020 Mar 31;14(1):44. doi: 10.1186/s13256-020-02367-z. PMID: 32234068Free PMC Article
Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients.
Lehnert T
Transplantation 1998 Nov 27;66(10):1307-12. doi: 10.1097/00007890-199811270-00007. PMID: 9846513

Clinical prediction guides

A new schedule of one week on/one week off temozolomide as second-line treatment of advanced neuroendocrine carcinomas (TENEC-TRIAL): a multicenter, open-label, single-arm, phase II trial.
von Arx C, Della Vittoria Scarpati G, Cannella L, Clemente O, Marretta AL, Bracigliano A, Picozzi F, Iervolino D, Granata V, Modica R, Bianco A, Mocerino C, Di Mauro A, Pizzolorusso A, Di Sarno A, Ottaiano A, Tafuto S; ENETs Center of Excellence in Naples, Italy and with the endorsement of the Italian Association for Neuroendocrine Tumor IT.A.NET
ESMO Open 2024 May;9(5):103003. Epub 2024 Apr 13 doi: 10.1016/j.esmoop.2024.103003. PMID: 38615472Free PMC Article
Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d'Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network.
Hadoux J, Kanaan C, Durand A, Hescot S, Hautefeuille V, Cadiot G, Tauveron I, Laboureau S, Do Cao C, Walter T, Petorin C, Blanchet O, Jannin A, Gu C, Faron M, Leteurtre E, Rousselet MC, Zakeyh JJ, Marchal A, Chatelain D, Beaulaton C, Hervieu V, Ducreux M, Scoazec JY, Baudin E
Eur J Cancer 2021 Jul;152:100-115. Epub 2021 Jun 3 doi: 10.1016/j.ejca.2021.04.030. PMID: 34090142
Amrubicin in patients with platinum-refractory metastatic neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the gastrointestinal tract.
Araki T, Takashima A, Hamaguchi T, Honma Y, Iwasa S, Okita N, Kato K, Yamada Y, Hashimoto H, Taniguchi H, Kushima R, Nakao K, Boku N, Shimada Y
Anticancer Drugs 2016 Sep;27(8):794-9. doi: 10.1097/CAD.0000000000000393. PMID: 27341105
Mifepristone Treatment of Cushing's Syndrome in a Pediatric Patient.
Banerjee RR, Marina N, Katznelson L, Feldman BJ
Pediatrics 2015 Nov;136(5):e1377-81. Epub 2015 Oct 12 doi: 10.1542/peds.2015-0684. PMID: 26459648
Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT.
Bruzzi JF, Macapinlac H, Tsimberidou AM, Truong MT, Keating MJ, Marom EM, Munden RF
J Nucl Med 2006 Aug;47(8):1267-73. PMID: 16883004

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...